Early recognition and treatment strategies for fibrotic interstitial lung disease in China
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
This study is trying to find better ways to recognize and treat fibrotic interstitial lung disease in China by looking at a large group of patients and testing new methods for diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06655090 on ClinicalTrials.gov |
What this trial studies
This project aims to create a large cohort of over 10,000 cases of fibrotic interstitial lung disease (f-ILD), including a significant number of pneumoconiosis cases, to study clinical phenotypes associated with pulmonary fibrosis. The study will evaluate the safety and effectiveness of various biopsy techniques and optimize histological diagnosis methods for f-ILD. Additionally, it will develop an artificial intelligence system for assessing the severity of pulmonary fibrosis and identify important molecular targets and biomarkers. The ultimate goal is to establish early recognition models and intervention strategies for f-ILD that can be applied nationwide.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with interstitial lung disease.
Not a fit: Patients who lack a chest CT or refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and treatment strategies for patients with fibrotic interstitial lung disease.
How similar studies have performed: Other studies have shown success in utilizing similar approaches for early recognition and treatment of interstitial lung diseases, indicating potential for this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed as ILD Exclusion Criteria: * Lack of chest CT * Patients refused to participant
Where this trial is running
Beijing, Beijing Municipality
- China-Japan Friendship Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Huaping Dai, M.D. Ph.D.
- Email: daihuaping@sina.com
- Phone: 0086-10-84206271
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.